Use of 2,4-pyrimidinediamines for the treatment of atherosclerosis

Details for Australian Patent Application No. 2009215430 (hide)

Owner Rigel Pharmaceuticals, Inc.

Inventors Masuda, Esteban; Schmitz, Jochen

Agent Spruson & Ferguson

Pub. Number AU-A-2009215430

PCT Pub. Number WO2009/105675

Priority 61/030,903 22.02.08 US

Filing date 20 February 2009

Wipo publication date 27 August 2009

International Classifications

A61K 31/5383 (2006.01)

A61K 31/662 (2006.01) - Phosphorus acids or esters thereof having PC bonds, e.g. foscarnet, trichlorfon

A61P 9/10 (2006.01) Drugs for disorders of the cardiovascular system

Event Publications

9 September 2010 PCT application entered the National Phase

  PCT publication WO2009/105675 Priority application(s): WO2009/105675

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2009215436-Postsynaptically targeted chemodenervation agents and their methods of use

2009215427-Chemo-mechanical polishing of dentures